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ABSTRACT
Introduction: To evaluate the efficacy and
safety of a pseudoceramide-containing
moisturizer as maintenance therapy in patients
with mild-to-moderate atopic dermatitis (AD).
Methods: This was a prospective, single-arm,
open-label clinical trial of a twice-daily
application of a pseudoceramide-containing
moisturizer for 4 weeks as maintenance
therapy in 40 patients with stable, mild-to-
moderate AD in a tropical climate. Clinical and
skin barrier assessment was done at week 0,
week 2 and week 4. Any adverse effects were
also recorded during the study period.
Results: The objective scoring atopic
dermatitis decreased from 29.1 [interquartile
range (IQR) 21.9–33.7] at week 0 to 22.0
(IQR 21.2–27.8) at week 4 (p\0.001). There
was no detectable difference in transepidermal
water loss after 4 weeks; however, stratum
corneum (SC) hydration was significantly
increased from 39.7 (IQR 35.3–46.4) at week
0 to 49.2 (IQR 41.2–54.6) after 4 weeks
(p\0.001). Both Dermatology Life Quality
Index and patient-oriented eczema measure
showed significant improvement at week 4
(p\0.001). The moisturizer was well
tolerated with no serious adverse events
recorded.
Conclusion: After 4 weeks of barrier
maintenance therapy with a pseudoceramide
moisturizer, there was a significant
improvement in disease severity, SC hydration
and quality of life in both pediatric and adult
patients with mild-to-moderate AD.
Keywords: Atopic dermatitis; Ceramides;
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INTRODUCTION
Atopic dermatitis (AD) is a chronic, relapsing,
inflammatory skin disease causing impaired
quality of life. AD affects about 10–30% of
children and 2–10% of adults [1–4].
Skin barrier dysfunction plays a critical role
in the initiation, perpetuation and exacerbation
of AD and the key players for a normal
epidermal barrier function include lipids and
proteins in the stratum corneum. Ceramides are
the major constituent (50%) of these lipids [5]
and have been shown to have a high water-
holding capacity [6]. Patients with AD have
been shown to have lower levels of ceramides,
particularly type 1 and 3 [7, 8]. More recent
studies have shown that in addition to the
reduction of ceramides in AD skin, an increased
level of short-chain ceramides can lead to an
aberrant lipid organization and decreased skin
barrier function in AD patients [9, 10]. Hence, a
therapeutic approach to repair the skin barrier
defect in AD is to normalize the amount of
ceramides in the skin. The use of ceramide
containing topical creams has been shown to be
beneficial in the management of AD [11–13].
However, additional research is needed to
determine the optimal formulary compositions.
Ceramides can be extracted from natural
animal sources, but this process is lengthy and
expensive with limited availability.
Furthermore, there are concerns about the
toxicity and the risk of transmissible
infections, such as bovine spongiform
encephalopathy, from bovine-derived sources
[14]. Hence, synthetic pseudoceramides, which
have been developed and used successfully in
skin barrier repair therapy [15, 16], have a good
safety profile and are less expensive than
natural ceramides [5, 14].
The primary objective of this study was to
demonstrate the safety and efficacy of the use of
a pseudoceramide-containing moisturizer in
both adults and children with mild-to-
moderate AD as maintenance therapy in a
tropical climate. Secondary aims were to
evaluate skin physiological measurements and
also the patients’ acceptability and adherence to
the moisturizer.
METHODS
This was a prospective, 4-week, non-controlled
open-label clinical trial to determine the safety
and efficacy of a twice-daily application of a
pseudoceramide moisturizer for the
maintenance therapy of mild-to-moderate AD
in both children and adults.
The test product in this study was Curel
Moisture cream (Kao Corporation, Tokyo,
Japan), which contained 8% of a synthetic
pseudoceramide, sphingolipid E (cetyl-
propyleneglycolhydroxy-ethylpalmitamide),
which is analogous to endogenous ceramide
type 2. It also contained Eucalyptus globules
extract that has been shown to increase
endogenous production of ceramides by
keratinocytes [17]. The full ingredients of the
study cream are listed in Table 1. Earlier animal
safety studies have shown that it is non-toxic
[18–20].
Study Subjects
Forty subjects were recruited from the
outpatient dermatology clinics at the National
Skin Centre, Singapore. Inclusion criteria
included an unequivocal diagnosis of AD
based on the UK Working Party’s Group
criteria [21], age between 7–60 years old, with
stable, mild-to-moderate AD as defined by
objective SCORing Atopic Dermatitis
(SCORAD) scores of \15 for mild AD, and
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15–40 for moderate AD [22–24]. Exclusion
criteria were a recent disease flare or the use of
any systemic therapy, including antibiotics,
phototherapy, corticosteroids or
immunosuppressants, within the past 4 weeks.
Study Design
There were a total of three study visits, namely,
week 0, week 2 and week 4. At each visit, study
subjects underwent clinical examination
(including evaluation of any adverse events),
skin physiological measurements and
completed questionnaires related to quality of
life, adverse events and their use of the study
cream. The study was conducted in Singapore,
which has a tropical climate with no seasonal
variation. All subjects were instructed to use the
study cream at least twice a day for 4 weeks on
all affected areas as well as other body areas,
including the forearms and cubital fossae.
Subjects were allowed to use their standard
medicated creams as needed, in event of a
disease flare. No other moisturizers were
allowed during the study period and all
subjects were provided with a standardized
soap-free cleanser for bathing. The use of
topical corticosteroids was documented, and
the amount of the study cream used was
assessed by recording the weight of the
returned containers at the end of the study
period.
Clinical Assessment of AD Severity
Disease severity of AD was assessed using the
objective and total SCORAD index and the
three-item-severity (TIS) scores (maximum TIS
score 9) [22–24]. Each case was evaluated by the
same dermatologist to minimize inter-observer
variability.
Skin Physiological Studies
Standardized measurements of stratum
corneum (SC) hydration and transepidermal
water loss (TEWL) were performed by a single
technician. Testing was performed at a fixed
Table 1 Contents for Curel Moisture cream (Kao Corporation, Tokyo, Japan) moisture cream
Allantoin Magnesium sulfate
Bis-methoxypropylamido isodocosane Methyl paraben
Butylene glycol Neopentyl glycol dicaprate
Cetyl dimethicone PEG-5 hydrogenated castor oil
Cetyl-propyleneglycolhydroxy-ethylpalmitamide,
8% synthetic pseudoceramide (Sphingolipid E)
PEG-12 dimethicone
Cyclopentasiloxane Polyglyceryl-2 Diisostearate
Dextrin palmitate Sodium hydroxide
Dimethicone Squalane
Dipentaerythrityl hexahydroxystearate Succinic acid
Eucalyptus globulus leaf extract Tocopherol
Glycerine Trisiloxane
Isostearyl glyceryl ether Water
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point, defined as 3 cm distal from the cubital
crease over the flexor aspect of both forearms.
Measurements were taken in triplicate for each
site, the mean value being used for analysis.
There was a washout period of 3 days prior to
baseline measurements (visit 1), and subjects
were instructed not to use any topical products
on both forearms.
SC hydration was measured using a
Corneometer CM 825 (Courage & Khazaka
GmbH, Cologne, Germany) and expressed in
arbitrary units between 0 and 130. A value [50
from the arms was interpreted as sufficiently
moisturized, 35–50 as dry and \35 as very dry
[25, 26]. TEWL was obtained using a
Tewameter TM 300 (Courage & Khazaka
GmbH, Cologne, Germany) and recorded as
g/m2/h. All measurements were performed in
the same room with a controlled temperature of
25 C, after a 15-min acclimatization.
Patient’s Assessment of AD severity
Subjective scores included the Dermatology Life
Quality Index (DLQI) (maximum DLQI score
30) [27, 28] and the patient-oriented eczema
measure (POEM) (maximum POEM score 28)
[29, 30]. Both the adult or pediatric versions of
the DLQI and POEM were used accordingly. In
addition, subjective scores for both pruritus and
insomnia (scale from 0 to 10) were analyzed
during the study period. The subject’s
evaluation of the study cream was also
assessed at the end of the study.
Statistical Analysis
Changes in disease severity scores, skin
physiological measurements and patient
subjective severity scores were analyzed at
week 0, week 2 and week 4. Intention-to-treat
analysis was performed. Given that these
measurements were not normally distributed,
the median and interquartile range (IQR) was
used as descriptive statistics and overall
improvements were analyzed using Friedman
test. When there was significant overall
improvement, post hoc pairwise comparison
between weeks was conducted using the
Wilcoxon signed-rank test with Bonferroni
correction to test the median for paired
results. The data were analyzed using SPSS
version 21 (SPSS Inc., Chicago, IL, USA).
Differences were considered significant at
p\0.05.
This study was approved by the institution’s
Domain Specific Review Board. All procedures
followed were in accordance with the ethical
standards of the Helsinki Declaration of 1975, as
revised in 2000 and 2008. Written informed




A total of 40 subjects with mild-to-moderate AD
were recruited. There were 26 adults and 14
children (Table 2). The majority were male
(75%, n = 30) and Chinese (92.5%, n = 37),
with a median age of 20.5 years (range 7–37).
The overall median objective SCORAD at
baseline was 29.1 (IQR 21.9–33.7).
Clinical Assessment of AD severity
There was an improvement in the SCORAD and
TIS scores at week 2 and week 4. At week 2, the
objective SCORAD decreased to 25.1 (IQR
19.3–29.2) and at week 4, there was a further
decrease to 22.0 (IQR 21.2–27.8) (Fig. 1). The
median total SCORAD showed a similar
reduction during the study period (Table 3).
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Both overall reduction of objective SCORAD and
total SCORAD were statistically significant
(p\0.001). The mean TIS score also decreased
over4 weeks fromabaselinescoreof3 (IQR3–5) to
2 points (IQR 1–3) at week 4 (p\0.001) (Table 3).
Skin Physiological Measurements
SC hydration improved in 29 (85%) of the study
subjects. The median of skin hydration at
baseline was 39.7 (IQR 35.3–46.4) and
increased to 49.2 (IQR 41.2–54.6) at week 4
(p\0.001) (Table 3).
Paradoxically, the median TEWL increased
from 9.4 at baseline to 11.2 at week 4 (p = 0.1)
(Table 3).
Patient Subjective symptoms
There was improvement in DLQI from a median
baseline score of 6.5 (IQR 3–11) to 3 (IQR 2–7) at
week 4 (p\0.001) (Table 3). The POEM showed
a similar improvement: from 13 (IQR 2–7) at
baseline to 6.5 (IQR 2–7) at week 4 (p\0.001)
(Table 3). The pruritus score was reduced from 6
(IQR 5–7) to 4 (IQR 2–6) over the study period
(p\0.001). A noticeable but not statistically
significant improvement was seen in the
insomnia score: from 2 (IQR 0–6) points on
the visual analogue scale (VAS) scale to 0 (IQR
0–3) points at week 4 (p = 0.03).
Adverse Events
At week 2, five (12.5%) subjects reported
pruritus and one (2.5%) patient reported
Table 2 Demographic details and clinical characteristics of the patients
Total (n5 40) Adults 17–60 years (n5 26) Children 7–16 years (n5 14)
Ethnicity
Chinese 37 25 12
Malay 1 0 1
Indian 1 1 0
Others 1 0 1
Gender
Male 30 23 7
Female 10 3 7
Age (year) median (range) 20.5 (7–37) 22 (17–37) 10 (7–16)
Median Total SCORAD (IQR) 38.8 (28.6–43.8) 41.3 (20.2–51.0) 28.5 (14.7–53.0)
IQR interquartile range, SCORAD scoring atopic dermatitis
Fig. 1 Objective scoring atopic dermatitis (SCORAD)
assessment shows clinical improvement after 4 weeks use of
the pseudoceramide-containing moisturizer
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warmth sensation after application of the test
cream. At week 4, 2 (5%) patients reported
pruritus after application of the test product.
One patient discontinued the creams at week 3
after he developed worsening of rashes and
acneiform papules on the face. There were no
other serious adverse events noted.
Patient Adherence and Evaluation
At the end of the study period, 23 (57.5%) of the
subjects rated the study cream as excellent or
very good, 13 (32.5%) rated it as good and the
remaining 4 (10%) rated it as fair. The majority
(82.5%) of subjects liked the cream and reported
that it improved dryness, provided symptom
relief and improved skin texture.
Treatment compliance was assessed by the
physician; 27 (67.5%) patients were reported to
have excellent compliance, 11 (27.5%) moderate
compliance and 2 (5%) poor compliance.
There was a wide variation in the total
quantity of study cream used with a mean
quantity of 94 g (range 12–396 g, n = 34). There
was no difference in the amount used by adults or
children. No correlation between the quantity of
cream used and the improvement in objective
SCORAD during the study period was found.
Prior to study inclusion, all participants used
topical corticosteroids. At the final follow-up, 5
(12.5%) subjects had discontinued the use of
topical corticosteroids.
DISCUSSION
This prospective open-label clinical trial found
that the use of a pseudoceramide moisturizer
was effective in improving disease severity,
stratum corneum hydration, itch scores and
quality of life indices in both pediatric and adult
patients with mild or moderate AD. After a
4-week use of the pseudoceramide moisturizer,
there was improvement in objective and total
SCORAD, TIS, DLQI and POEM scores, which
was statistically significant. This is in agreement
with previous studies which showed that the
use of ‘‘physiologic’’ ceramide moisturizers was
effective in improving disease severity,
decreasing steroid use and preventing disease
flares [11, 12, 31]. This underscores the
importance of long-term skin barrier repair in
the maintenance therapy of AD [32, 33].
While SC hydration improved significantly,
it was interesting that the authors did not find
any significant difference for TEWL
measurements. Standardization of TEWL
measurements can be technically difficult and
similar paradoxical findings have been reported
in other moisturizer studies [13, 31, 34, 35].
Furthermore, SC hydration is a more sensitive
measure of the skin barrier function than TEWL
in AD patients [36], as the relationship between
TEWL and skin dryness is complex, whereby
changes in dryness do not necessarily reflect
simultaneous changes in TEWL [37].
The pseudoceramide moisturizer was safe
and well tolerated with only 5% of patients
reporting pruritus after application. Only 1
patient discontinued with the moisturizer
shortly before the end of the study because of
a facial rash. It is well established that topical
applications, including placebo creams, can
cause a transient itch or stinging [38, 39]. In
general, the cream was very well tolerated and
the majority of patients had positive opinions
regarding the efficacy and cosmetic
acceptability of the creams. On average, 94 g
of the study cream was used during the whole
study period. This may be considered low, but it
is noted that subjects were only provided with
one 72 g tube of study cream every 2 weeks.
Despite a smaller body surface area, children
were found to have used the same amount of
study cream as adult subjects.
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This study had several limitations, namely, the
small study size, non-blinded design, short
duration and the lack of a control arm. The
authors also did not obtain information on the
exact amount of pseudoceramide moisturizer or
topical corticosteroids used over specific affected
areas.
CONCLUSION
This study showed that the regular use of a
pseudoceramide-containing moisturizer was
effective and safe as maintenance therapy in
mild-to-moderate AD patients. Further
additional, larger comparative trials against
placebo creams or ‘‘standard’’ non-lipid-based
moisturizers would be needed to further clarify
the exact contributory role of lipid-based
moisturizers in AD therapy.
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